Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer
Open Access
- 27 July 2010
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 103 (5), 649-655
- https://doi.org/10.1038/sj.bjc.6605819
Abstract
Background: Methods: Results: Conclusion:Keywords
This publication has 36 references indexed in Scilit:
- Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic CancerScience, 2009
- Targeting the mTOR Signaling Network for Cancer TherapyJournal of Clinical Oncology, 2009
- Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic CancerJournal of Clinical Oncology, 2009
- Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic AnalysesScience, 2008
- Pharmacodynamic-Guided Modified Continuous Reassessment Method–Based, Dose-Finding Study of Rapamycin in Adult Patients With Solid TumorsJournal of Clinical Oncology, 2008
- Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient GlioblastomaPLoS Medicine, 2008
- Exploiting the PI3K/AKT Pathway for Cancer Drug DiscoveryNature Reviews Drug Discovery, 2005
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences, 2005
- FRA3B and other common fragile sites: the weakest linksNature Reviews Cancer, 2001
- PTEN , a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate CancerScience, 1997